The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of docetaxel and irinotecan (DI) in children and young adults with recurrent or refractory Ewing sarcoma family of tumor (ESFT).
Jong Hyung Yoon
No relevant relationships to disclose
Hyeon Jin Park
No relevant relationships to disclose
Byung-Kiu Park
No relevant relationships to disclose